Tyra Biosciences CFO acquires 1,376 ESPP shares

Tyra Biosciences, Inc. Chief Financial Officer Alan Fuhrman increased his holdings through the company’s employee stock purchase plan.

Rhea-AI Filing Summary

Tyra Biosciences, Inc. Chief Financial Officer Alan Fuhrman increased his holdings through the company’s employee stock purchase plan. On March 13, 2026, he acquired 1,376 shares of common stock at $9.129 per share under the 2021 Employee Stock Purchase Plan. After this ESPP acquisition, he directly owns 16,164 common shares, reflecting a routine, compensation-related increase rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 1,376 shares

Grant/Award 1 txn

Insider Fuhrman Alan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,376	$9.129	$13K

Holdings After Transaction: Common Stock — 16,164 shares (Direct)

Footnotes (1)

1. F1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

FAQ

What insider transaction did Tyra Biosciences (TYRA) report for Alan Fuhrman?

Tyra Biosciences reported that CFO Alan Fuhrman acquired 1,376 shares of common stock. The shares were obtained on March 13, 2026 under the company’s 2021 Employee Stock Purchase Plan, reflecting a routine, compensation-related increase in his direct ownership position.

At what price did Tyra Biosciences CFO acquire new TYRA shares?

CFO Alan Fuhrman acquired 1,376 Tyra Biosciences common shares at $9.129 per share. The shares were purchased through the 2021 Employee Stock Purchase Plan, indicating a structured, program-based acquisition rather than a discretionary open-market buy order in the company’s stock.

How many Tyra Biosciences (TYRA) shares does Alan Fuhrman own after this Form 4?

After the reported transaction, CFO Alan Fuhrman directly owns 16,164 shares of Tyra Biosciences common stock. This total reflects the addition of 1,376 shares acquired on March 13, 2026 through the company’s 2021 Employee Stock Purchase Plan as disclosed in the Form 4 filing.

Was the Tyra Biosciences CFO’s TYRA share acquisition an open-market purchase?

No, the acquisition was not an open-market purchase. The Form 4 and footnote state that Alan Fuhrman obtained 1,376 common shares under Tyra Biosciences’ 2021 Employee Stock Purchase Plan, classed as a grant or award-type acquisition rather than a market trade.

What does the transaction code 'A' mean in Tyra Biosciences CFO’s Form 4?

The transaction code “A” on the Form 4 indicates a grant, award, or other acquisition of securities. For Tyra Biosciences’ CFO, this code reflects 1,376 common shares acquired on March 13, 2026 under the 2021 Employee Stock Purchase Plan, not a standard market purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 04:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fuhrman Alan

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A(1)	V	1,376	A	$9.129	16,164	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

	/s/ Ali D. Fawaz, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.